Search results
Showing 31 to 45 of 60 results for attention deficit hyperactivity disorder
Autism spectrum disorder in under 19s: support and management
Suspected neurological conditions: recognition and referral (NG127)
This guideline covers the initial assessment of symptoms and signs that might indicate a neurological condition. It helps non-specialist healthcare professionals to identify people who should be offered referral for specialist investigation.
Show all sections
This guideline covers preventing, assessing and managing mental health problems in people with learning disabilities in all settings (including health, social care, education, and forensic and criminal justice). It aims to improve assessment and support for mental health conditions, and help people with learning disabilities and their families and carers to be involved in their care.
Mental health of adults in contact with the criminal justice system (NG66)
This guideline covers assessing, diagnosing and managing mental health problems in adults (aged 18 and over) who are in contact with the criminal justice system. It aims to improve mental health and wellbeing in this population by establishing principles for assessment and management, and promoting more coordinated care planning and service organisation across the criminal justice system.
Our health inequalities guidance supports strategies that improve population health as a whole, while offering particular benefit to the most disadvantaged
Evidence-based recommendations on selumetinib (Koselugo) for treating symptomatic and inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in children aged 3 and over.
Attention deficit hyperactivity disorder: diagnosis and management (CG72)
This guidance has been updated and replaced by NICE guideline NG87.
This guideline covers recognising and responding to abuse and neglect in children and young people aged under 18. It covers physical, sexual and emotional abuse, and neglect. The guideline aims to help anyone whose work brings them into contact with children and young people to spot signs of abuse and neglect and to know how to respond. It also supports practitioners who carry out assessments and provide early help and interventions to children, young people, parents and carers.
All NICE products on attention deficit disorder. Includes any guidance, advice and quality standards.
This quality standard covers diagnosing and managing epilepsies in children, young people and adults. It describes high-quality care in priority areas for improvement.
View quality statements for QS211Show all sections
Sections for QS211
- Quality statements
- Quality statement 1: Referral and assessment after first seizure
- Quality statement 2: Referral to tertiary specialist services
- Quality statement 3: Epilepsy specialist nurse
- Quality statement 4: Epilepsy care plan
- Quality statement 5: Mental health and wellbeing
- Quality statement 6: Neurodevelopment and learning disabilities
- Update information
Attention deficit hyperactivity disorder in children and young people: clonidine (ESUOM8)
This evidence summary has been updated and replaced by NICE guideline NG87.
This evidence summary has been updated and replaced by NICE guideline NG87.
This guidance has been updated and replaced by NICE guideline NG87.
This evidence summary has been updated and replaced by NICE guideline NG87.
This guidance has been replaced by NICE technology appraisal guidance 98 [Replaced by NICE guideline NG87].